ONCOLOGY
Scope & Guideline
Innovating the future of oncology with every publication.
Introduction
Aims and Scopes
- Clinical Research and Trials:
The journal publishes studies related to clinical trials, treatment efficacy, and patient outcomes across various cancer types, emphasizing evidence-based approaches. - Biomarkers and Genomic Profiling:
Research focusing on the identification and validation of biomarkers for prognosis and treatment response, as well as genomic studies that explore the molecular underpinnings of cancer. - Innovative Therapeutic Strategies:
Papers that evaluate new therapeutic approaches, including immunotherapy, targeted therapies, and combination treatments, are a core focus, reflecting the journal's commitment to cutting-edge cancer care. - Epidemiology and Risk Factors:
The journal addresses the epidemiology of cancers, identifying risk factors and patterns of disease, which is crucial for public health and preventive strategies. - Patient-Centered Care and Quality of Life:
Research exploring the psychosocial aspects of cancer care, including quality of life, patient-reported outcomes, and supportive care, is emphasized to ensure holistic treatment approaches. - Technological Innovations in Oncology:
Studies that incorporate advanced technologies such as artificial intelligence and imaging techniques in cancer diagnosis and treatment are also featured, highlighting the journal's forward-looking perspective.
Trending and Emerging
- Immunotherapy and Checkpoint Inhibitors:
There is a marked increase in studies evaluating the efficacy and safety of immunotherapies, particularly immune checkpoint inhibitors, reflecting their pivotal role in modern oncology. - Personalized Medicine and Genomic Medicine:
Research into personalized treatment approaches based on genomic profiling is trending, highlighting the importance of tailoring therapies to individual patient characteristics. - Real-World Evidence and Outcomes Research:
Emerging themes include the use of real-world data to assess treatment outcomes, patient experiences, and the effectiveness of therapies outside of clinical trial settings. - Quality of Life and Patient-Reported Outcomes:
An increasing number of studies are focusing on the quality of life, survivorship issues, and the psychosocial aspects of cancer treatment, emphasizing patient-centered care. - Artificial Intelligence and Big Data in Oncology:
The integration of artificial intelligence and big data analytics in cancer research and treatment planning is gaining momentum, indicating a transformative shift in the field.
Declining or Waning
- Traditional Chemotherapy Approaches:
Historically significant, traditional chemotherapy research is becoming less prominent as newer treatment modalities like immunotherapy and targeted therapy gain traction in the field. - Single-Agent Studies:
Research focusing solely on the efficacy of single-agent chemotherapy treatments has decreased, reflecting a broader understanding of the importance of combination therapies. - Palliative Care Research:
While still important, the volume of studies specifically centered on palliative care approaches and end-of-life issues has seen a decline, possibly overshadowed by advancements in curative treatment options. - Basic Science and Laboratory Studies:
There has been a noticeable shift away from basic science research towards more clinically relevant studies, indicating a move towards translational research that directly impacts patient care. - Radiation Therapy Studies:
The focus on traditional radiation therapy studies appears to be waning, with fewer publications compared to the rising interest in integrating radiation with systemic therapies.
Similar Journals
JAMA Oncology
Elevating the standards of cancer research excellence.JAMA Oncology, published by the American Medical Association, stands at the forefront of cancer research as a premier peer-reviewed journal in the field. With an ISSN of 2374-2437 and an impressive impact factor reflecting its critical insights, the journal has achieved a top-tier position, being ranked in the Q1 quartile for both Cancer Research and Oncology as of 2023, and demonstrating exceptional performance in Medicine as well. Spanning a converged publication period from 2015 through 2024, JAMA Oncology publishes cutting-edge research, clinical trials, and reviews that are pivotal in advancing our understanding and treatment of cancer. The journal's Scopus ranks highlight its global impact, placing it in the top deciles within its categories, ensuring that it remains a vital resource for oncologists, researchers, and students alike. While it currently does not offer open access, JAMA Oncology continues to provide invaluable contributions to the scientific community, promoting a deeper understanding of oncological challenges and breakthroughs.
World Journal of Clinical Oncology
Transforming Patient Care through Groundbreaking ResearchWorld Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Illuminating the Pathways of Cancer Discovery and Treatment.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.
South Asian Journal of Cancer
Fostering innovation in South Asian cancer research.South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.
Frontiers in Oncology
Pioneering new frontiers in cancer knowledge and treatment.Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.
Cancer Management and Research
Illuminating the complexities of oncology for better health.Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.
CANCER
Driving innovation in cancer treatment and biology.CANCER, published by Wiley, stands as a pivotal journal in the field of oncology and cancer research, boasting an impressive impact factor and consistently dynamic growth since its inception in 1948. With an ISSN of 0008-543X and an E-ISSN of 1097-0142, this esteemed journal is recognized for its rigorous peer-reviewed articles, making significant contributions to the understanding of cancer biology, treatment modalities, and clinical practices. CANCER holds a distinguished position in the academic community, securing its placement in the Q1 category for both cancer research and oncology, and ranks within the top percentiles on Scopus, indicating its high impact and relevance. The journal is particularly beneficial for researchers, professionals, and students seeking to stay abreast of the latest advancements in cancer science. By addressing essential research questions and providing pathways for new therapies, CANCER continues to play a crucial role in shaping the future of oncology and improving patient outcomes.
CANCER INVESTIGATION
Illuminating pathways in oncology through peer-reviewed excellence.CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
Navigating the Landscape of Cancer TrialsAMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.
Nature Reviews Clinical Oncology
Shaping the Future of Oncology with EvidenceNature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.